Series B and $4m grant breathe life into Savara's AeroVanc
This article was originally published in Scrip
Executive Summary
Savara Pharmaceuticals has closed the second $7.4 million tranche for its $16 million Series B funding round and received a $4 million federal grant to finance a Phase IIa study for AeroVanc, the company's inhaled vancomycin powder product candidate for the treatment of lung infections in cystic fibrosis patients.